Trial record 1 of 6 for:
zimura
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03364153 |
|
Recruitment Status :
Recruiting
First Posted : December 6, 2017
Last Update Posted : January 19, 2021
|
Sponsor:
IVERIC bio, Inc.
Information provided by (Responsible Party):
IVERIC bio, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
To evaluate the safety and efficacy of Zimura™ (complement factor C5 inhibitor) compared to Sham in subjects with autosomal recessive Stargardt disease 1 (STGD1).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Stargardt Disease 1 | Drug: Zimura Other: Sham | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease |
| Actual Study Start Date : | January 12, 2018 |
| Estimated Primary Completion Date : | March 2023 |
| Estimated Study Completion Date : | March 2023 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1
Zimura dose group
|
Drug: Zimura
Zimura Intravitreal Injection
Other Name: avacincaptad pegol |
|
Sham Comparator: Cohort 2
Sham dose group
|
Other: Sham
Sham Intravitreal Injection |
Primary Outcome Measures :
- Spectral Domain-Optical Coherence Tomography (SD-OCT) [ Time Frame: 18 months ]Mean rate of change in the area of ellipsoid zone defect measured by en face SD-OCT
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- At least two pathogenic mutations of ABCA4 gene confirmed by a CLIA-certified laboratory
- Best corrected visual acuity in the study eye between 20/20 - 20/200 Snellen equivalent, inclusive
Exclusion Criteria:
- Macular atrophy secondary to any condition other than STGD1 in either eye
- Any prior treatment for STGD1 including gene therapy, stem cell therapy or any prior intravitreal treatment for any indication in either eye
- Participation in an interventional study of a vitamin A derivative ≤ 3 months prior to screening
- Presence of intraocular inflammation, macular hole, pathologic myopia, epiretinal membrane, evidence of significant vitreo-macular traction, vitreous hemorrhage or aphakia
- Any intraocular surgery or thermal laser within 3 months of trial entry. Any prior thermal laser in the macular region
- Diabetes mellitus
- HbA1c value of ≥6.5%
- Stroke within 12 months of trial entry
- Any major surgical procedure within one month of trial entry or anticipated during the trial
- Any treatment with an investigational agent in the past 60 days for any condition
- Women who are pregnant or nursing
- Known serious allergies to the fluorescein dye used in angiography, povidone iodine, or to the components of the Zimura formulation
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03364153
Contacts
| Contact: Sonia Cruz | 347-322-8722 | sonia.cruz@ophthotech.com |
Locations
Show 40 study locations
Sponsors and Collaborators
IVERIC bio, Inc.
| Responsible Party: | IVERIC bio, Inc. |
| ClinicalTrials.gov Identifier: | NCT03364153 |
| Other Study ID Numbers: |
OPH2005 |
| First Posted: | December 6, 2017 Key Record Dates |
| Last Update Posted: | January 19, 2021 |
| Last Verified: | January 2021 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by IVERIC bio, Inc.:
|
Zimura ARC1905 complement factor C5 inhibitor avacincaptad pegol STGD1 |
Additional relevant MeSH terms:
|
Macular Degeneration Retinal Degeneration Retinal Diseases Eye Diseases |